Fused heterocyclic compound
Small organic compounds targeting USP1 inhibit its activity, addressing the need for therapeutic agents in cancer and metabolic disorders by leveraging USP1's role in DNA repair and metabolic regulation.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- AIGEN SCIENCES INC
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
There is a need for a novel small organic molecule compound capable of inhibiting the activity of the deubiquitination enzyme USP1, which is overexpressed in various cancer cells and plays a crucial role in DNA damage repair, offering potential therapeutic targets for cancer and metabolic disorders.
Development of small organic compounds defined by specific chemical formulas (e.g., Formula 1, Formula 2, Formula 3) that inhibit USP1 activity, including their tautomers, stereoisomers, and pharmaceutically acceptable salts, targeting USP1 for selective inhibition in cancer treatment and metabolic diseases.
The compounds effectively inhibit USP1 activity, demonstrating synthetic lethality with BRCA activity, providing therapeutic potential for treating BRCA-mutated cancers and metabolic disorders such as diabetes and obesity.
Smart Images
Figure KR2025021046_18062026_PF_FP_ABST